CHDI Foundation

30 July 2020

Molecular Design Platform Accelerating Research For Huntington’s Disease

OpenEye Scientific and CHDI Foundation Announce Collaboration on Small-Molecule Computational Research for Huntington’s Disease

SANTA FE, N.M., & NEW YORK, N.Y. – July 28, 2020 – OpenEye Scientific (OpenEye) and CHDI Foundation (CHDI) today announced a research collaboration to identify novel small-molecule therapeutics for Huntington’s disease (HD) utilizing Orion, OpenEye’s cloud-native molecular design platform. Read more…

16 March 2020

A letter from Robert Pacifici PhD, Chief Scientific Officer, CHDI, to our collaborators about working practices during the pandemic

Dear CHDI Collaborator:

The current coronavirus pandemic is affecting all of us in very unwelcomed and uncertain ways. First and foremost, I’m reaching out to you on behalf of all of us at CHDI to express our sincere wishes that you, your colleagues and institution, and your families are coping with the circumstances as best you can. Read more…